Featured Articles

  1. How NeuroKit® Helps Avoid False Negatives in Early CNS Development 7/30/2026

    Detecting subtle CNS effects early can reduce false negatives. Sensitive assessments strengthen confidence in pharmacodynamic signals and dose selection.

     

  2. EU Clinical Trial Regulation Timelines: Shorter Than Many Expect 7/30/2026

    The EU CTR rewards early planning. Strong documentation, regulatory readiness, and aligned partners can help accelerate approvals and reduce delays.

  3. Building Recruitment Into Early-Phase Trial Design 7/30/2026

    Successful recruitment starts with smart study design. Early recruitment insight improves feasibility, supports realistic timelines, and reduces enrollment risk.

  4. Balancing Patient Convenience And Signal Integrity In CNS Trials 7/30/2026

    Early CNS trials depend on precise data. Hybrid approaches can reduce participant burden, but critical assessments often require controlled environments to preserve signal integrity.

  5. A Sponsor's Guide To Evaluating CRO Data Governance 7/30/2026

    Evaluate CRO data governance with a risk-based framework that strengthens data quality, traceability, compliance, and regulatory readiness.

  6. Interpreting Early Inflammation Signals: What Early Human Data Tells Us 7/10/2026

    Early inflammatory signals can mislead without context. Benchmarked human challenge models reveal true biological activity, guiding decisions on mechanism, dosing, and clinical development.

  7. Why Benchmarking Inflammatory Models Matters: What Early Human Data Tells Us 7/6/2026

    Benchmarking immune challenge models clarifies early pharmacodynamic signals, helping teams distinguish true target engagement from variability, prioritize endpoints, and make confident decisions.

  8. Expression Of Key Immunology Drug Targets In Human Inflammatory Challenge Models 7/6/2026

    Human challenge models reveal immune pathway behavior in controlled settings, linking early research to outcomes and helping confirm target engagement, refine dosing, and reduce development uncertainty.

  9. How Pharmacometrics Informs Dose Selection And Biomarker Decisions 6/10/2026

    Quantitative modeling guides early dose and biomarker insights, reducing uncertainty, improving study design, and enabling faster, more confident decisions from first trials to clinical progress.

  10. Why Early Clinical Development Is Shifting Toward Decision-Enabling Study Designs 6/9/2026

    Early clinical research is shifting to decision-focused designs, using biomarkers, functional endpoints, and targeted populations to reduce uncertainty and enable clearer progression.